Regeneron has identified hundreds of coronavirus antibodies for developing treatments for COVID-19 and hopes to start clinical trials by early summer.
The company said it has isolated virus-neutralizing, human antibodies that could be used as either prophylaxis before exposure to the virus, or to treat those already infected. The antibodies were identified from mice genetically modified to have human immune systems.
Regeneron plans to select the top two antibodies for a cocktail treatment based on potency and ability to bind to the coronavirus. The multi-antibody approach can target different parts of the virus and may help protect against multiple viral variants.